The prognostic value of preoperative serum levels of IL-12p40 and IL-23 for survival of patients with colorectal cancer

APMIS

Volumn 122, Issue 12, 2014, Pages 1223-1229

  Stanilov, Noyko ^a,b   Miteva, Lyuba ^a   Jovchev, Jovcho ^a   Cirovski, Geo ^a,c   Stanilova, Spaska ^a  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c Hospital 'St Ivan Rilski'   (Bulgaria)

Author keywords

CRC; Cytokines; IL 12p40; IL 23; Survival

Indexed keywords

INTERLEUKIN 12P40; INTERLEUKIN 23; IL12B PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR INVASION; BLOOD; COLORECTAL NEOPLASMS; KAPLAN MEIER METHOD; MIDDLE AGED; PROGNOSIS;

AGED; COLORECTAL NEOPLASMS; FEMALE; HUMANS; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-23; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84922480473     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12288     Document Type: Article

References (33)

1. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009;22:191-7.
2. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004;21:137-48.
3. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004;4:11-22.
4. Kaminska J, Kowalska MM, Nowacki MP, Chwalinski MG, Rysinska A, Fuksiewicz M. CRP, TNFα, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000;6:38-41.
5. Stanilov N, Miteva L, Deliyski T, Jovchev J, Stanilova S. Advanced colorectal cancer is associated with enhanced Interleukin-23 and Interleukin -10 serum level. Lab Med 2010;41:159-63.
6. Stanilov N., Stankova N, Miteva L, Jovchev J, Deliyski T, Stanilova S. Role of IL-12p40 and IL-10 in progression of colorectal cancer. Trakia J Sci 2010;8(suppl.2):132-6.
7. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Danilidis K, Theodoropoulos G, et al. Serum IL-6, TNFα and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol 2005;11:1639-43.
8. Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I - An independent prognostic factor. Tumor Biol 2005;26:186-94.
9. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
10. Gately MK, Desai BB, Wolitzky AG, Quinn PM, Dwyer CM, Podlaski FJ, et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-82.
11. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003;3:133-46.
12. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003;19:641-4.
13. Cooper AM, Khader SA. IL-12p40: an inherently agonistic cytokine. Trends Immunol 2007;28:33-8.
14. Jana M, Dasgupta S, Saha RN, Liu X, Pahan K. Induction of tumor necrosis factor-a (TNF-a) by interleukin-12 p40 monomer and homodimer in microglia and macrophages. J Neurochem 2003;86:519-28.
15. Holscher C, Atkinson RA, Arendse B, Brown N, Myburgh E, Alber G, Brombacher F. A protective and agonistic function of IL-12p40 in mycobacterial infection. J Immunol 2001;167:6957-66.
16. Lehmann J, Bellmann S, Werner C, Schröder R, Schütze N, Alber G. IL-12p40-dependent agonistic effects on the development of protective innate and adaptive immunity against Salmonella enteritidis. J Immunol 2001;167:5304-15.
17. Reinhardt RL, Hong S, Kang SJ, Wang ZE, Locksley RM. Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. J Immunol 2006;177:1618-27.
18. Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, et al. Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000;13:715-25.
19. Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, et al. Both IL-12p70 and IL-23 Are synthesized during active crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006;12:9-15.
20. Grivennikov SI, Wang K, Mucida D, Stewart C, Schnabl B, Jauch D, et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254-8.
21. Tejpar S, Bertagnolli M, Bosman F, Lenz HJ, Garraway L, Waldman F, et al. Prognostic and predictive biomarkers in resected colon cancer: current status and future perspectives for integrating genomics into biomarker discovery. Oncologist 2010;15:390-404.
22. McDonald JR, Renehan AG, O'Dwyer ST, Haboubi NY. Lymph node harvest in colon and rectal cancer: current considerations. World J Gastrointest Surg 2012;4:9-19.
23. Wong KP, Poon JT, Fan JK, Law WL. Prognostic value of lymph node ratio in stage III colorectal cancer. Colorectal Dis 2011;13:1116-22.
24. Akagi Y, Adachi Y, Kinugasa T, Oka Y, Mizobe T, Shirouzu K. Lymph node evaluation and survival in colorectal cancer: review of population-based, Prospective Studies. Anticancer Res 2013;33:72839-47.
25. Wang CS, Sun CF. CRP and malignancy Clinico-pathological association and therapeutic implication. Chang Gung Med J 2009;32:471-82.
26. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
27. Ko YJ, Kwon YM, Kim KH, Choi HC, Chun SH, Yoon HJ, et al. High-Sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev 2012;21:2076-8.
28. Groblewska MMB, Wereszczynska-Siemiatkowska U, Kedra B, Lukaszewicz M, Baniukiewicz A, Szmitkowski M. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med 2008;46:1423-8.
29. Toiyama Y, Fujikawa H, Koike Y, Saigusa S, Inoue Y, Tanaka K, et al. Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment. Oncol Lett 2013;5:1881-8.
30. Heikkilä KES, Lawlor DA. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. Eur J Cancer 2008;44:937-45.
31. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, Pelosio L, et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 2002;102:169-78.
32. Lan F, Zhang L, Wu J, Zhang J, Zhang S, Li K, et al. IL-23/IL-23R: potential mediator of intestinal tumor progression from adenomatous polyps to colorectal carcinoma. Int J Colorectal Dis 2011;26:1511-8.
33. Miteva L, Stanilov N, Deliysky T, Mintchev N, Stanilova S. Association of polymorphisms in regulatory regions of interleukin-12p40 gene and cytokine serum level with colorectal cancer. Cancer Invest 2009;27:924-31.